

## Special Issue

# Antibody–Drug Conjugates Therapeutics

### Message from the Guest Editors

Antibody–drug conjugates (ADCs) are a promising class of cancer therapeutics. These conjugates consist of a monoclonal antibody linked to cytotoxic agents through chemical linkers. By leveraging the high specificity of monoclonal antibodies, ADCs enable precise drug delivery to target tissues, thereby enhancing the overall therapeutic index. The development of ADCs, however, is complex and faces numerous challenges, such as antigen selection, linker stability, drug resistance, and toxicity management. This Special Issue will focus on recent advancements in ADC design. Topics will include novel conjugation techniques, innovative payloads, improved linker technologies, and next-generation ADC platforms. Additionally, this Special Issue will explore mechanisms of action, clinical applications, and strategies to enhance therapeutic efficacy. Contributions on combination therapies, bispecific ADCs, and applications beyond oncology are also welcome. Both original research papers and comprehensive review articles are encouraged to contribute to the evolving landscape of ADC-based therapeutics. We look forward to receiving your valuable contributions.

### Guest Editors

Prof. Dr. Amal Ali Elkordy

School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK

Dr. Summer Y. Y. Ha

Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA

### Deadline for manuscript submissions

20 November 2025



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/239004](https://mdpi.com/si/239004)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).